TY  - GEN
AU  - Personeni,Nicola
AU  - Rimassa,Lorenza
AU  - Verusio,Claudio
AU  - Barni,Sandro
AU  - Rubino,Luca
AU  - Bozzarelli,Silvia
AU  - Villa,Eugenio
AU  - Carnaghi,Carlo
AU  - Tronconi,Maria Chiara
AU  - Gerardi,Chiara
AU  - Galli,Francesca
AU  - Floriani,Irene
AU  - Destro,Annarita
AU  - Raschioni,Carlotta
AU  - Labianca,Roberto
AU  - Santoro,Armando
TI  - FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study
SN  - 1938-0674
PY  - 2016///0519
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Camptothecin
KW  - Cetuximab
KW  - administration & dosage
KW  - Colorectal Neoplasms
KW  - drug therapy
KW  - Disease-Free Survival
KW  - Female
KW  - Fluorouracil
KW  - Gene Expression Regulation, Neoplastic
KW  - Humans
KW  - Leucovorin
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Neoplasm Metastasis
KW  - PTEN Phosphohydrolase
KW  - genetics
KW  - Prognosis
KW  - Prospective Studies
KW  - Proto-Oncogene Proteins B-raf
KW  - Proto-Oncogene Proteins c-met
KW  - Proto-Oncogene Proteins p21(ras)
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.clcc.2015.02.006
ER  -